MattelNASDAQ: MAT

Mattel announced that 80% of its games will be colorblind accessible by the end of 2024. The company plans to raise this amount to 90% in 2025.

BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at New York Presbyterian/Weill Cornell Medical Center and was discharged after just six weeks of treatment with MAT2203, Matinas' oral formulation of the potent antifungal amphotericin B. The patient was treated under Matinas' Compassionate/ Expanded Use Access Program by Sharan Yadav, MD, Infectious Disease Fellow.

Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung and bladder cancer patients in H2 2024, including RECIST 1.1 clinical efficacy waterfall, swim-lane plot, ctDNA molecular response analysis, AE profile, PK and pharmacodynamics Initiating IDE397 Phase 2 monotherapy expansion in MTAP bladder cancer, in addition to the earlier reported Phase 2 expansion in MTAP squamous lung cancer Activated over 35 clinical trial sites globally across the U.S., Canada, Europe, and Asia Pacific to enable potential rapid enrollment for the IDE397 Phase 2 clinical program SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced clinical program updates for IDE397, a potential first-in-class Phase 2 MAT2A inhibitor targeting MTAP-deletion solid tumors.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, will be featured in a fireside chat with David S.

EL SEGUNDO, Calif.--(BUSINESS WIRE)--The California State Legislature has recognized Mattel for its dedication to creating play experiences that bring joy and enrichment to children's lives as part of proclaiming today, June 11, 2024, as International Day of Play in California. This inaugural International Day of Play (IDOP) is a global movement adopted by the United Nations certifying that play is a fundamental right for every child. The resolution passed, marking California as the first west.

Mattel's (MAT) focus on digital gaming and location-based entertainment will likely drive growth. However, an uncertain macroeconomic environment is a concern.

EL SEGUNDO, Calif. & LONDON--(BUSINESS WIRE)--Mattel, Inc. (Nasdaq: MAT), a leading global toy and family entertainment company and owner of one of the most iconic brand portfolios in the world, in collaboration with Outright Games, the leading publisher of family-friendly interactive entertainment, has today revealed the first all-console and PC video game inspired by the die-cast collectible toy brand Matchbox™. Developed by Casual Brothers, Matchbox Driving Adventures will be available Septe.

Mattel (MAT) teams up with Universal Pictures to develop a live-action feature film based on the teenage girl fashion doll line.